Table 1.

Patient characteristics

CHARACTERISTIC	1-year survivors	2-year survivors	3-year survivors	5-year survivors
N	272	232	203	157
Median age at AHCT (range), years	56 (19–78)	56 (19–78)	55 (19–76)	53 (19–75)
Sex, N (%)
Male	165 (60.7)	140 (60.3)	120 (59.1)	96 (61.1)
Female	107 (39.3)	92 (39.7)	83 (40.9)	61 (38.9)
Race, N (%)
Non-Hispanic White	253 (93.0)	214 (92.2)	186 (91.6)	142 (90.4)
African-American	14 (5.1)	14 (6.0)	13 (6.4)	11 (7.0)
Hispanic	4 (1.5)	3 (1.3)	3 (1.5)	3 (1.9)
Other	1 (0.4)	1 (0.4)	1 (0.5)	1 (0.6)
IPI at diagnosis, N (%)
Low/low intermediate	191 (74.3)	165 (74.7)	146 (74.5)	115 (73.7)
High intermediate/High	66 (25.7)	56 (25.3)	50 (25.5)	41 (26.3)
Unknown	15	11	7	1
IPI at AHCT, N (%)
Low/low intermediate	197 (73.2)	164 (71.6)	146 (72.3)	113 (72.4)
High intermediate/High	72 (26.8)	65 (28.4)	56 (27.7)	43 (27.6)
Unknown	3	3	1	1
B symptoms at diagnosis, N (%)	121 (45.1)	106 (46.1)	96 (47.5)	78 (49.7)
B symptoms pre-AHCT, N (%)	20 (7.4)	19 (8.2)	19 (9.4)	15 (9.6)
Transformed DLBCL, N (%)	59 (21.7)	52 (22.4)	46 (22.7)	38 (24.2)
Stage at diagnosis, N (%)
I	21 (7.8)	15 (6.6)	12 (5.9)	9 (5.8)
II	37 (13.8)	31 (13.5)	28 (13.9)	22 (14.1)
III	62 (23.0)	52 (22.7)	44 (21.8)	34 (21.8)
IV	149 (55.4)	131 (57.2)	118 (58.4)	91 (58.3)
Unknown	3	3	1	1
Median time from diagnosis to AHCT (range), months	18.5 (0.9–372.3)	18.4 (0.9–372.3)	18.5 (0.9–372.3)	16.1 (0.9–372.3)
≥ 3 chemotherapy regimens prior to AHCT	73 (26.9)	59 (25.4)	50 (24.6)	35 (22.3)
Prior rituximab, N (%)	221 (81.2)	192 (82.8)	167 (82.3)	124 (79.0)
Prior radiation, N (%)	77 (28.3)	61 (26.3)	57 (28.1)	42 (26.8)
Performance status at AHCT, N (%)
Good (ECOG ≤1/KPS ≥80)	249 (95.8)	210 (95.5)	185 (96.4)	144 (98.0)
Poor (ECOG >1/KPS <80)	11 (4.2)	10 (4.5)	7 (3.6)	3 (2.0)
Unknown	12	12	11	10
Disease risk category, N (%)*
Low	9 (3.3)	9 (3.9)	8 (3.9)	7 (4.5)
Intermediate	238 (87.5)	203 (87.5)	179 (88.2)	139 (88.5)
High	25 (9.2)	20 (8.6)	16 (7.9)	11 (7.0)
Chemotherapy mobilization, N (%)	210 (77.2)	181 (78.0)	161 (79.3)	129 (82.2)
Mean CD34+ dose (standard deviation), ×106/kg	8.99 (8.44)	9.04 (8.52)	9.49 (8.92)	10.36 (9.56)
Conditioning regimen, N (%)
Bu/Cy/VP	264 (97.1)	226 (97.4)	197 (97.0)	152 (96.8)
Other	8 (2.9)	6 (2.6)	6 (3.0)	5 (3.2)
Mean duration of AHCT hospitalization (standard deviation), days	22 (3)	22 (2)	22 (2)	21 92)
Relapse after AHCT but prior to inclusion in the cohort, N (%)	41 (15.1)	36 (15.5)	34 (16.7)	23 (14.6)
Median follow-up of alive patients (range), months	95.9 (15.8–198.4)	96.9 (26.6–198.4)	108.2 (37.2–198.4)	119.0 (60.0–198.4)

AHCT indicates autologous hematopoietic cell transplantation; IPI International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; Bu/Cy/VP, Busulfan/Cyclophosphamide/Etoposide

^*Disease risk category includes: Low risk – first complete remission; Intermediate risk – second or greater complete remission or partial remission; high-risk – primary refractory or resistant relapse or never treated